Dissociation of lung function, dyspnea ratings and pulmonary extension in bronchiectasis
- PMID: 17698334
- DOI: 10.1016/j.rmed.2007.06.028
Dissociation of lung function, dyspnea ratings and pulmonary extension in bronchiectasis
Abstract
Bronchiectasis is a heterogeneous disease in terms of its clinical and functional presentation. Some isolated parameters have been used to assess the severity of bronchiectasis or its response to treatment. A study was undertaken to evaluate whether lung function, dyspnea and extension of the disease are separate entities in the impact of bronchiectasis upon patients using factor analysis. Patients with bronchiectasis diagnosed by high-resolution computed tomography (HRCT) and airflow obstruction defined by FEV1/FVC<70% were included. Data were collected relating to clinical history, three different clinical ratings of dyspnea (Medical Research Council (MRC), Borg scale and Basal Dyspnea Index), the extent of bronchiectasis and functional variables. A total of 81 patients (mean age (SD): 69.5 (8.7)) years were included. The degree of dyspnea (MRC) was 1.9 (0.8). Mean FEV1 was 1301 ml (56.9% pred.). Four factors were found that accounted for 84.1% of the total data variance. Factor 1 (45.6% of the data variance) included the three measurements of dyspnea. Factor 2 (16% variance) comprised airflow obstruction parameters (FEV1, FEV1/FVC and PEF). Factor 3 (13.8% variance) included RV/TLC and RV (lung hyperinflation). Factor 4 (8.6% variance) included bronchiectasis extent. Dyspnea was more closely correlated with lung hyperinflation (r:0.33-0.54) than with airflow obstruction parameters (r:0.17-0.26).
Conclusions: Airflow obstruction, dyspnea, lung hyperinflation and the lung extent of the bronchiectasis are four independent entities in the impact of bronchiectasis upon patients.
Similar articles
-
Tidal expiratory flow limitation, dyspnoea and exercise capacity in patients with bilateral bronchiectasis.Eur Respir J. 2003 May;21(5):743-8. doi: 10.1183/09031936.03.00301103. Eur Respir J. 2003. PMID: 12765414
-
A factor analysis of dyspnea ratings, respiratory muscle strength, and lung function in patients with chronic obstructive pulmonary disease.Am Rev Respir Dis. 1992 Feb;145(2 Pt 1):467-70. doi: 10.1164/ajrccm/145.2_Pt_1.467. Am Rev Respir Dis. 1992. PMID: 1736759 Clinical Trial.
-
Factor analysis of laboratory and clinical measurements of dyspnea in patients with chronic obstructive pulmonary disease.J Pain Symptom Manage. 2003 Feb;25(2):118-27. doi: 10.1016/s0885-3924(02)00690-5. J Pain Symptom Manage. 2003. PMID: 12590027 Clinical Trial.
-
Factors associated with pulmonary hypertension and long-term survival in bronchiectasis subjects.Respir Med. 2016 Oct;119:109-114. doi: 10.1016/j.rmed.2016.08.027. Epub 2016 Aug 30. Respir Med. 2016. PMID: 27692130 Review.
-
Prognostic performance of the FACED score and bronchiectasis severity index in bronchiectasis: a systematic review and meta-analysis.Biosci Rep. 2020 Oct 30;40(10):BSR20194514. doi: 10.1042/BSR20194514. Biosci Rep. 2020. PMID: 33057706 Free PMC article.
Cited by
-
Quality of life and its determinants in patients with noncystic fibrosis bronchiectasis.J Res Med Sci. 2021 May 27;26:27. doi: 10.4103/jrms.JRMS_665_20. eCollection 2021. J Res Med Sci. 2021. PMID: 34345238 Free PMC article.
-
Peripheral Neutrophil-to-Lymphocyte Ratio in Bronchiectasis: A Marker of Disease Severity.Biomolecules. 2022 Sep 30;12(10):1399. doi: 10.3390/biom12101399. Biomolecules. 2022. PMID: 36291608 Free PMC article.
-
The Human Mycobiome in Chronic Respiratory Diseases: Current Situation and Future Perspectives.Microorganisms. 2022 Apr 13;10(4):810. doi: 10.3390/microorganisms10040810. Microorganisms. 2022. PMID: 35456861 Free PMC article. Review.
-
The impact of COPD-bronchiectasis association on clinical outcomes: insights from East Asian cohorts validating the ROSE criteria.ERJ Open Res. 2025 Mar 10;11(2):00626-2024. doi: 10.1183/23120541.00626-2024. eCollection 2025 Mar. ERJ Open Res. 2025. PMID: 40071267 Free PMC article.
-
Rationale and Clinical Use of Bronchodilators in Adults with Bronchiectasis.Drugs. 2022 Jan;82(1):1-13. doi: 10.1007/s40265-021-01646-3. Epub 2021 Nov 26. Drugs. 2022. PMID: 34826104
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical